Table 1.
Patient, Tumor and Treatment Characteristics (Table reproduced from reference # 28).
| Variable | All Patients (n = 76) | Oropharynx (n = 46) |
|---|---|---|
| Patient characteristics | N (%) | N (%) |
| Age at Completion of Treatment, median (range) | 63 (19 – 86) | 62 (30 – 77) |
| Sex | ||
| Female | 19 (25) | 8 (17.4 %) |
| Male | 57 (75) | 38 (82.6 %) |
| Race | ||
| African American | 15 (19.7) | 9 (19.6) |
| Asian | 4 (5.3) | 0 |
| Caucasian | 49 (64.5) | 32 (69.6) |
| Hispanic | 6 (7.9) | 3 (6.5) |
| Not Specified | 2 (2.7) | 2 (4.3) |
| BMI, median (range) | 24.3 (17.3 – 34.4) | 24.3 (17.3 – 33.2) |
| Smoking Status | ||
| Current | 2 (2.6) | 0 |
| Former | 44 (57.9) | 25 (54.3) |
| Never | 30 (39.5) | 21 (45.7) |
| Lymphedema Outcome | ||
| External Lymphedema | 52 (68.4) | 36 (78.3) |
| Internal Lymphedema | 30 (39.5) | 17 (37) |
| External & Internal Lymphedema | 23 (30.3) | 15 (32.6) |
| Tumor Characteristics | ||
| Subsite | ||
| Hypopharynx | 2 (2.6) | – |
| Larynx | 14 (18.4) | – |
| Nasopharynx | 5 (6.6) | – |
| Oral Cavity | 5 (6.6) | – |
| Oropharynx | 46 (60.5) | 46 (1 0 0) |
| Other (parotid, sinus & paranasal sinus) | 4 (5.3) | – |
| Grouped† T Stage | ||
| Tis | 2 (2.6) | 0 |
| T1 | 20 (26.3) | 17 (37.0) |
| T2 | 22 (28.9) | 14(30.4) |
| T3 | 13 (17.1) | 5 (10.9) |
| T4 | 19 (25) | 10 (21.8) |
| Consensus‡ T Stage | ||
| T0 | 2 | 0 |
| T1 | 20 | 17 |
| T2 | 22 | 14 |
| T3 | 13 | 5 |
| T4 | 3 | 2 |
| T4a | 14 | 7 |
| T4b | 2 | 1 |
| Grouped†† N Stage | ||
| Group 0 | 16 | 5 |
| Group 1 | 18 | 11 |
| Group 2 | 9 | 7 |
| Group 3 | 12 | 8 |
| Group 4 | 21 | 15 |
| Consensus‡ N Stage | ||
| N0 | 16 (21.1) | 5 (10.9) |
| N1 | 10 (13.2) | 3 (6.5) |
| N2 (nasopharynx only) | 2 (2.6) | |
| N2a | 8 (10.3) | 8 (17.4) |
| N2b | 9 (11.8) | 7 (15.2) |
| N2c | 10 (13.2) | 8 (17.4) |
| N3 (nasopharynx only) | 1 (1.3) | 0 |
| N3a | 0 | 0 |
| N3b | 20 (26.3) | 15 (32.6) |
| Bulky Nodes* | ||
| No | 43 (56.6) | 23 (50.0) |
| Yes | 33 (43.4) | 23 (50.0) |
| Location of lymph node metastases | ||
| None | 16 (21.1) | 5 (10.9) |
| Unilateral | 41 (53.9) | 29 (63.0) |
| Bilateral | 19 (25) | 12 (26.1) |
| Treatment Characteristics | ||
| Surgery Variables | ||
| Surgical Resection | ||
| No | 48 (63.2) | 29 (63.0) |
| Yes | 26 (34.2) | 17 (37.0) |
| Laryngectomy | 2 (2.63) | 0 |
| Neck Dissection | ||
| None | 50 (65.8) | 29 (63.0) |
| Unilateral (Ipsilateral) | 20 (26.3) | 4 (8.7) |
| Bilateral | 6 (7.9) | 13 (28.3) |
| Number of lymph nodes removed, average (IQR) | 11.5 (0 – 20) | 12.2 (0 – 21) |
| Radiation Variables | ||
| Radiation Type | ||
| Adjuvant | 28 (36.8) | 17 (37.0) |
| Definitive | 48 (63.2) | 29 (63.0) |
| Radiation treatment of neck | ||
| None | 6 (7.9) | 0 |
| Unilateral (Ipsilateral) | 11 (14.5) | 6 (13.1) |
| Bilateral | 59 (77.6) | 40 (87.0) |
| Radiation modality | ||
| Photon | 70 (92.1) | 42 (91.3) |
| Proton | 6 (7.9) | 4 (8.7) |
| Radiation delivery | ||
| 2-field | 6 (7.9) | 0 |
| SIB | 57 (75) | 38 (82.6) |
| Sequential | 7 (9.2) | 4 (8.7) |
| Proton | 6 (7.9) | 4 (8.7) |
| EQD2, median (range) | 7000 (5200 – 7066) | 7000 (5600 – 7066) |
| Days of radiation, median (range) | 46 (28–70) | 48 (37 – 54) |
| Chemotherapy Variables | ||
| Induction chemotherapy | ||
| No | 71 (93.4) | 42 (91.3) |
| Yes | 5 (6.6) | 4 (8.7) |
| Concurrent chemotherapy | ||
| No | 21 (27.6) | 8 (17.4) |
| Yes | 55 (72.4) | 38 (82.6) |
| Adjuvant chemotherapy | ||
| No | 72 (94.7) | 46 (1 0 0) |
| Yes | 4 (5.3) | 0 |
*Bulky nodes defined as N2c or greater, or N2 and greater for nasopharynx.
† Grouped T staging defined as T0 – T4, with substages T4a and T4b combined into single group T4.
†† Grouped N staging defined as:
0 = N0.
1 = N1 & N2a (includes nasopharynx).
2 = N2b.
3 = N2 (nasopharynx) and N2c.
4 = N3 (nasopharynx) and N3b.
‡ Consensus defined as highest T or N stage between clinical and pathologic staging.
IQR = Interquartile range.
SIB = simultaneous integrated boost.